A first-in-human phase I/II clinical trial of NIR-PIT using cetuximab-IR700 (RM-1929) targeting epidermal growth factor receptor (EGFR) in patients with inoperable head and neck squamous cell cancer (HNSCC) was successfully completed in late 2017 (https://clinicaltrials. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.